Tight junctions are the most apical components of endothelial and epithelial intercellular cleft. In the endothelium these structures play an important role in the control of paracellular permeability to circulating cells and solutes. The only known integral membrane protein localized at sites of membrane–membrane interaction of tight junctions is occludin, which is linked inside the cells to a complex network of cytoskeletal and signaling proteins. We report here the identification of a novel protein (junctional adhesion molecule [JAM]) that is selectively concentrated at intercellular junctions of endothelial and epithelial cells of different origins. Confocal and immunoelectron microscopy shows that JAM codistributes with tight junction components at the apical region of the intercellular cleft. A cDNA clone encoding JAM defines a novel immunoglobulin gene superfamily member that consists of two V-type Ig domains. An mAb directed to JAM (BV11) was found to inhibit spontaneous and chemokine-induced monocyte transmigration through an endothelial cell monolayer in vitro. Systemic treatment of mice with BV11 mAb blocked monocyte infiltration upon chemokine administration in subcutaneous air pouches. Thus, JAM is a new component of endothelial and epithelial junctions that play a role in regulating monocyte transmigration.
Skip Nav Destination
Article navigation
13 July 1998
Article|
July 13 1998
Junctional Adhesion Molecule, a Novel Member of the Immunoglobulin Superfamily That Distributes at Intercellular Junctions and Modulates Monocyte Transmigration
In Special Collection:
JCB65: Cell Adhesion and Migration
Inés Martìn-Padura,
Inés Martìn-Padura
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Search for other works by this author on:
Susan Lostaglio,
Susan Lostaglio
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Search for other works by this author on:
Markus Schneemann,
Markus Schneemann
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Search for other works by this author on:
Lisa Williams,
Lisa Williams
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Search for other works by this author on:
Maria Romano,
Maria Romano
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Search for other works by this author on:
Paolo Fruscella,
Paolo Fruscella
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Search for other works by this author on:
Carla Panzeri,
Carla Panzeri
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Search for other works by this author on:
Antonella Stoppacciaro,
Antonella Stoppacciaro
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Search for other works by this author on:
Luigi Ruco,
Luigi Ruco
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Search for other works by this author on:
Antonello Villa,
Antonello Villa
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Search for other works by this author on:
David Simmons,
David Simmons
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Search for other works by this author on:
Elisabetta Dejana
Elisabetta Dejana
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Search for other works by this author on:
Inés Martìn-Padura
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Susan Lostaglio
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Markus Schneemann
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Lisa Williams
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Maria Romano
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Paolo Fruscella
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Carla Panzeri
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Antonella Stoppacciaro
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Luigi Ruco
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Antonello Villa
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
David Simmons
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Elisabetta Dejana
*Istituto di Ricerche Farmacologiche Mario Negri, 20157 Milano, Italy; ‡Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, United Kingdom; §Dipartimento di Farmacologia, Universita degli Studi di Milano, and DIBIT, Milano, Italy 20129; and ‖Universita' degli Studi La Sapienza, Dipartimento di Medicina Sperimentale e Patologia, 00161 Roma, Italy
Address all correspondence to Inés Martìn-Padura, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, 20157 Milano, Italy. Tel.: 39-2-39014477; Fax: 39-2-3546277; E-mail: [email protected]
Received:
October 31 1997
Revision Received:
May 27 1998
Online ISSN: 1540-8140
Print ISSN: 0021-9525
1998
J Cell Biol (1998) 142 (1): 117–127.
Article history
Received:
October 31 1997
Revision Received:
May 27 1998
Citation
Inés Martìn-Padura, Susan Lostaglio, Markus Schneemann, Lisa Williams, Maria Romano, Paolo Fruscella, Carla Panzeri, Antonella Stoppacciaro, Luigi Ruco, Antonello Villa, David Simmons, Elisabetta Dejana; Junctional Adhesion Molecule, a Novel Member of the Immunoglobulin Superfamily That Distributes at Intercellular Junctions and Modulates Monocyte Transmigration . J Cell Biol 13 July 1998; 142 (1): 117–127. doi: https://doi.org/10.1083/jcb.142.1.117
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement
Advertisement